RT @doctorRBC: Mavrilimumab (GM-CSFi) phase II trial of COVID-19 PNA and systemic hyperinflammation âï¸65% risk redu
Tweet Content
Mavrilimumab (GM-CSFi) phase II trial of COVID-19 PNA and systemic hyperinflammation
⭐️65% risk reduction in ventilation/death
⭐️no sig difference in ventilation requirement
⭐️no serious AE
Abs#LB0001
#EULAR2021 @RheumNow
Show on Archive Page
On
Display in Search Results
On
PDQ
Off